Introduction to "nimesulide: beyond COX-2".
Warner
T D
TD
Department of Cardiac, Vascular and Inflammation Research, William Harvey Research Institute, St. Bartholomew's, Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, U.K. t.d.warner@mds.qmw.ac.uk
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000201:enzymology; D013379:Substrate Specificity; D013449:Sulfonamides / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D013449:Sulfonamides; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C012655:nimesulide